About Us

Amylyx is an clinical stage pharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases.

Our Team

CEO and Founder: Joshua Cohen
President and Founder: Justin Klee
Vice President, Research: Kent Leslie
Chairman of SAB: Dr. Rudolph Tanzi
Director: Steve Chubb
Director: George Milne
Director: Wally Gilbert

Latest News

Project ALS and Amylyx Enter Collaboration to Test AMX0035

New York, NY and Cambridge, MA
September 7, 2017

Learn More